{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:08Z","timestamp":1793061308058,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007540","name":"Jiangsu Provincial Agricultural Science and Technology Innovation Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102932","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:33:03Z","timestamp":1784730783000},"page":"102932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A poly(I:C)\/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance"],"prefix":"10.1016","volume":"7","author":[{"given":"Wenbo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyi","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-1429","authenticated-orcid":false,"given":"Xianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102932_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102932_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102932_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102932_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/0008-5472.CAN-23-2042","article-title":"Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines","volume":"84","author":"Pounraj","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102932_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102932_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113090","article-title":"A recent perspective on designing tumor vaccines for tumor immunology","volume":"142","author":"Cao","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2026.102932_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113927","article-title":"Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors","volume":"177","author":"Ye","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.102932_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102932_bib9","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102932_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102932_bib11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102932_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0391","article-title":"Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors","volume":"12","author":"M\u00e1rquez-Rodas","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102932_bib13","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102932_bib14","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102932_bib15","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-19-2217","article-title":"Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma","volume":"26","author":"Algazi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102932_bib16","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/ijms22041626","article-title":"Hiltonol Cocktail Kills Lung Cancer Cells by Activating Cancer-Suppressors, PKR\/OAS, and Restraining the Tumor Microenvironment","volume":"22","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.102932_bib17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0008-8749(84)90376-9","article-title":"Modulation of stimulatory effects of poly(I:C) on natural cytotoxicity by anti-interferon","volume":"86","author":"Droller","year":"1984","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0041-008X(72)90098-1","article-title":"Studies on poly I:C toxicity in experimental animals","volume":"23","author":"Homan","year":"1972","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102932_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13046-021-02017-2","article-title":"A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy","volume":"40","author":"De Waele","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102932_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","article-title":"Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action","volume":"5","author":"Pifferi","year":"2021","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.xcrm.2026.102932_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1517\/13543784.7.9.1475","article-title":"QS-21: a water-soluble triterpene glycoside adjuvant","volume":"7","author":"Kensil","year":"1998","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.xcrm.2026.102932_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","article-title":"Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine","volume":"12","author":"Fochesato","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.xcrm.2026.102932_bib24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102932_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1152934","article-title":"Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review","volume":"14","author":"Zhai","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102932_bib26","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cac2.12579","article-title":"\u201cFind Me\u201d and \u201cEat Me\u201d signals: tools to drive phagocytic processes for modulating antitumor immunity","volume":"44","author":"Xiao","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xcrm.2026.102932_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125334","article-title":"Not Just a Sum? Identifying Different Types of Interplay between Constituents in Combined Interventions","volume":"10","author":"Van Deun","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102932_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1146\/annurev.immunol.19.1.623","article-title":"IRF family of transcription factors as regulators of host defense","volume":"19","author":"Taniguchi","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib44","doi-asserted-by":"crossref","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.xcrm.2026.102932_bib45","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1039\/C4OB01652A","article-title":"The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells","volume":"12","author":"Lorent","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.xcrm.2026.102932_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.immuni.2019.07.007","article-title":"Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons","volume":"51","author":"Forero","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102932_bib31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib32","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102932_bib33","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.immuni.2022.07.021","article-title":"Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12","volume":"55","author":"Garris","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102932_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102932_bib35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102932_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cancers17050880","article-title":"Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy","volume":"17","author":"Almawash","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102932_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/cancers13030440","article-title":"Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies","volume":"13","author":"Pham","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102932_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102932_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrc3672","article-title":"Thermal ablation of tumours: biological mechanisms and advances in therapy","volume":"14","author":"Chu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102932_bib40","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO-24-02595","article-title":"BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203","volume":"43","author":"M\u00e1rquez-Rodas","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102932_bib41","article-title":"Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade","author":"Manriquez","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2026.102932_bib42","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acsptsci.4c00121","article-title":"Liposomes-Encapsulating Double-Stranded Nucleic Acid (Poly I:C) for Head and Neck Cancer Treatment","volume":"7","author":"Singh","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.xcrm.2026.102932_bib43","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1016\/j.apsb.2021.03.014","article-title":"Cytosolic delivery of the immunological adjuvant Poly I:C and cytotoxic drug crystals via a carrier-free strategy significantly amplifies immune response","volume":"11","author":"Du","year":"2021","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:24:32Z","timestamp":1793060672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003496"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102932","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A poly(I:C)\/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102932"}}